ExPlas

Phase 2Small molecule

NNorwegian University of Science and Technology

ExPlas is one of 13 small molecule programs targeting Early Alzheimer's Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Early Alzheimer's DiseaseRecruiting

Early Alzheimer's DiseasePhase 2

Recruiting

Competition

Competitive Landscape

13 competitors in Early Alzheimer's Disease

#DrugCompanyPhaseTrials

Kisunla

Eli Lilly

Phase 3

1 2

Tasigna

AAzurity Pharmaceuticals

Phase 3

1 3

Decadron

AAspen Global Incorporated

Phase 3

1 4

Leqembi

Eisai

Phase 2

5 5

Admsc

UUniversity Hospital, Toulouse

Phase 2

1 6

E2814

Eisai

Phase 2

1 7

JNJ-63733657

Johnson & Johnson

Phase 2

1 8

GSK4527226

GSK

Phase 2

1 9

Fasudil

WWoolsey Pharmaceuticals

Phase 2

1 10

ExPlas

NNorwegian University of Science and Technology

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Early Alzheimer's Disease1 trial

Safety and Efficacy of Plasma Transfusion From Exercise-trained Donors in Patients With Early Alzheimer's Disease

Recruiting·NNorwegian University of Science and Technology·Phase 2·NCT05068830·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ExPlas. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ExPlas compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ExPlas. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Norwegian University of Science and Technology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNorwegian University of Science and Technology

ExPlas

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Early Alzheimer's Disease1 trial

References

Drug Info

Quick Facts

Related News